RxDoctor Payments Data

Rachel Taylor

Family · Dyersburg, TNNPI 1376245902

Payments from drug & device makers

$3,891in general payments, 2019–2025

Across 200 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$752
  • Lilly USA, LLC$621
  • Boehringer Ingelheim$560
  • Bayer$348
  • AbbVie$290
  • Novartis$278
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,891100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,891 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$59,494
Medicare patients
283
Services billed
1,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide307$320,278
MounjaroTirzepatide259$292,853
JardianceEmpagliflozin260$181,997
TrulicityDulaglutide84$82,662
JanumetSitagliptin Phos/Metformin Hcl45$42,779
FarxigaDapagliflozin Propanediol70$40,188
JanuviaSitagliptin Phosphate25$26,433
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$23,523
Tresiba Flextouch U-100Insulin Degludec29$18,944
KerendiaFinerenone24$17,759
Janumet XrSitagliptin Phos/Metformin Hcl22$17,253
TradjentaLinagliptin24$12,893
Lantus SolostarInsulin Glargine,hum.Rec.Anlog81$12,181
Tresiba Flextouch U-200Insulin Degludec15$11,984
Fiasp FlextouchInsulin Aspart (Niacinamide)19$9,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$621$377,117357 claims
Novo NordiskOzempic$752$320,278307 claims
Boehringer IngelheimJardiance, Tradjenta$560$194,889284 claims
BayerKerendia$348$17,75924 claims
AbbVieSynthroid$290$3,54543 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$1,181151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Dyersburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →